Tissue repair & wound healing
Repair biology is the main reason TB-500 attracts attention, particularly where tissue recovery is slow or incomplete.
Explore the research →TISSUE REPAIR & REGENERATIVE RESEARCH
TB-500
TB-500 attracts interest around recovery, wound healing and the repair of tendons, ligaments and other soft tissues, although research remains largely preclinical.
Tissue repairTendon & ligamentAngiogenesis
Promising biological rationaleThe LKKTETQ actin-binding motif has preclinical support for cell migration and angiogenic activity. Direct human TB-500 evidence remains very limited, so related thymosin-beta-4 research is shown separately.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in TB-500?
TB-500 is mainly talked about for healing and recovery because the biology around it is connected with cell movement, new blood-vessel formation and tissue repair. Those processes are central to the way damaged tissue rebuilds itself, which is why TB-500 attracts particular interest around wounds, soft tissue and connective-tissue recovery.
Tendon & ligament recovery interest
TB-500 is widely discussed around tendon, ligament and soft-tissue recovery, making connective tissue one of its strongest areas of community interest.
Explore the research →Cell migration & actin biology
The short LKKTETQ sequence is especially interesting because it sits within the actin-binding region of thymosin β4.
Explore the research →Angiogenesis & vascular response
Formation of new microvessels is an important part of tissue repair and is one of the more compelling biological themes around the thymosin-β4 pathway.
Explore the research →THE SCIENCE BIT
A small fragment with a cell-movement story.
This profile uses TB-500 to mean the acetylated seven-amino-acid fragment from thymosin beta-4. Its sequence comes from an actin-related region of the larger peptide.
Actin is part of a cell's internal framework and helps cells change shape and move. Related fragment research explores migration and vessel formation; results for full thymosin beta-4 cannot automatically be transferred to TB-500.
See the studies & trials →- Actin
- Part of the cell's internal framework
- Migration
- Cell movement in repair models
- Fragment
- Distinct from full thymosin beta-4
How this connects to the research
Direct human evidence for this fragment remains limited.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where TB-500 connects with the body
These are the tissues and biological systems behind the interest in TB-500.
- Repair cells
- Fibroblast and endothelial movement.
- Connective tissue
- Experimental repair context.
- Small vessels
- Angiogenesis research.
The research behind the interest
Tissue repair & wound healing
Repair biology is the main reason TB-500 attracts attention, particularly where tissue recovery is slow or incomplete.
Thymosin β4 and its active-site sequences have shown effects on wound repair, cell migration and regenerative pathways in experimental models. Direct TB-500 evidence is much thinner.
Promising related-peptide evidenceExplore the studies →Tendon & ligament recovery interest
TB-500 is widely discussed around tendon, ligament and soft-tissue recovery, making connective tissue one of its strongest areas of community interest.
The biological rationale comes mainly from thymosin-β4 repair biology and actin-dependent cell movement rather than controlled human TB-500 injury trials.
Preclinical rationaleExplore the studies →Cell migration & actin biology
The short LKKTETQ sequence is especially interesting because it sits within the actin-binding region of thymosin β4.
Experimental research has linked this motif with actin-related biology, endothelial migration and other cellular processes involved in repair.
Mechanistic evidenceExplore the studies →Angiogenesis & vascular response
Formation of new microvessels is an important part of tissue repair and is one of the more compelling biological themes around the thymosin-β4 pathway.
A 2003 study found that a short actin-binding sequence containing LKKTETQ promoted endothelial migration, tubule formation and aortic-ring sprouting in experimental assays.
Strong motif-level preclinical signalExplore the studies →Inflammation & the repair environment
Recovery depends on more than rebuilding tissue; the local inflammatory and cellular environment also shapes the repair process.
Full-length thymosin β4 has been studied for anti-inflammatory and tissue-protective activity. How fully those effects carry across to TB-500 remains unresolved.
Related parent-peptide evidenceExplore the studies →Broader recovery potential
The combination of cell-migration, vascular and repair biology gives TB-500 a broad recovery story that continues to drive research and community interest.
Direct studies of TB-500 itself remain limited, but the surrounding thymosin-β4 literature provides several biologically plausible pathways worth investigating further.
Early exploratory evidenceExplore the studies →WHAT RESEARCH IS EXPLORING
A fragment built around a repair-related actin-binding motif
TB-500 is the acetylated 17–23 fragment of thymosin β4. Research around this sequence focuses on cell migration, angiogenesis and repair biology, while direct clinical studies of the fragment remain limited.
01Actin-binding motifLKKTETQ sits within the central actin-related region of thymosin β4.
02Cell migrationEndothelial and fibroblast movement is central to tissue repair.
03AngiogenesisRelated active-site research has reported vessel-formation signals.
04Tissue repairWound and connective-tissue biology explain much of the interest.
KEY STUDIES & EVIDENCE
Studies & evidence
TB-500 metabolism and wound-healing activity in vitro ↗
TB-500 metabolites were characterized after in-vitro and rat exposure.
PubMed · PMID 38382158 ↗The actin-binding site on thymosin beta4 promotes angiogenesis ↗
A short sequence containing the LKKTETQ actin-binding region showed angiogenic activity in experimental assays.
PubMed · PMID 14500546 ↗Biological activities of thymosin beta4 defined by active sites in short peptide sequences ↗
The LKKTETQ-containing actin-binding domain was associated with angiogenesis, wound healing and cell migration in experimental work.
PubMed · PMID 20179146 ↗Full-length thymosin β4 in dermal healing ↗
Human wound-healing research has been reported for full-length thymosin β4.
PubMed · PMID 23050815 ↗Why this still mattersRelated thymosin-β4 and motif research provide a credible biological rationale; direct TB-500 studies show how much of that promise translates to the fragment itself.
EVIDENCE SNAPSHOT
Evidence snapshot
◎
Human evidenceEarly
1/5 evidence depth
✓
Clinical efficacyEarly
1/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceEarly
1/5 evidence depth
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
HOW TO READ THESE SCORESDeveloping preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
Promising biological signals are visible in preclinical and related peptide research, while direct human TB-500 evidence remains early.
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with TB-500
Community interest in TB-500 is concentrated around injury recovery, tendons and ligaments, return to training and pairing it with BPC-157. Those experiences help identify the questions people care about most, while direct human TB-500 research remains limited.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Recovery from persistent soft-tissue problems
Tendon, ligament and muscle complaints draw interest from people whose activity has become restricted. The practical hope is a more reliable return to movement rather than repeatedly restarting after a flare.
- What makes a report informative
- Function at a comparable activity level and recurrence of symptoms.
- What can muddy the picture
- Rest, physiotherapy and changing training loads can explain improvement.
Less stiffness between training sessions
Some people are interested in more general recovery: feeling less beaten up and moving comfortably between sessions. This is broader and less clearly defined than recovery from a diagnosed injury.
- What makes a report informative
- Daily movement and recovery from a similar workload.
- What can muddy the picture
- Ordinary soreness varies with sleep, workload and nutrition.
The BPC-157 combination question
TB-500 is often discussed alongside BPC-157 in recovery conversations. The attraction is the idea of complementary repair effects, but combined use makes it difficult to attribute a result to either compound.
- What makes a report informative
- A complete account of compounds, rehabilitation and timing of changes.
- What can muddy the picture
- Human findings for full thymosin beta-4 cannot automatically be applied to the TB-500 fragment.
FROM PUBLIC DISCUSSIONS
Experiences worth looking at
Selected first-hand accounts illustrate the goals and the variation in experience. They are examples, not a representative sample or proof of an effect.
Recovery accounts involving BPC-157 and TB-500
Participants report different recovery experiences. Combination use means the thread cannot isolate a TB-500 effect.
Read the discussionPUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Faster tendon / ligament recovery
Human findings & limits
No direct controlled TB-500 efficacy trial identified
Laboratory & animal context
Related thymosin-β4 and actin-motif repair biology provides a plausible rationale
What this means: A major area of community interest with relevant biological support, but direct TB-500 human evidence is still needed.
Better soft-tissue recovery
Human findings & limits
Direct TB-500 evidence remains very limited
Laboratory & animal context
Cell-migration and wound-repair pathways are supported in related experimental research
What this means: The surrounding biology is encouraging enough to justify interest, while the fragment itself remains under-studied.
Improved repair environment / less inflammation
Human findings & limits
Not established for TB-500
Laboratory & animal context
Full-length thymosin β4 has anti-inflammatory and tissue-protective research
What this means: Related parent-peptide findings are interesting, but they should not be treated as proof of the same effect from TB-500.
BPC-157 + TB-500 works well as the Wolverine Stack
Human findings & limits
No controlled combination trial identified
Laboratory & animal context
Each component has a different surrounding research rationale
What this means: One of the best-known recovery stacks in peptide communities; combination-specific research would be needed to quantify any added effect.
Research sources and further reading
DOSE & DURATION
Research + community contextHow dosing is being explored
Direct human dosing data are not established, so research context and commonly repeated community patterns are shown separately.
WHAT THE RESEARCH CAN TELL USNo validated human TB-500 dose or titration schedule has been established.
No validated human dose-finding study establishes an amount, route or schedule for TB-500. The figures below are therefore presented only as community-described protocol patterns, not as a clinically validated regimen.
COMMONLY DISCUSSED PATTERNS
Community-described onlyHow community protocols are usually structured
LOADING PATTERN
Higher-frequency opening phase
- Amount commonly cited
- 2–2.5 mg per dose
- Frequency
- Twice weekly
- Approx. weekly total
- 4–5 mg/week
- Typical discussion window
- 4–6 weeks
MAINTENANCE PATTERN
Lower-frequency continuation
- Amount commonly cited
- 2–2.5 mg
- Frequency
- Once weekly or every other week
- Typical discussion window
- 4–8 weeks
- Evidence basis
- Anecdotal / community practice
BREAK / REASSESS
Pause rather than continuous use
- Amount
- None
- Commonly discussed break
- 4–8 weeks
- Purpose
- Reassess recovery and whether further use is being considered
- Evidence basis
- Community convention, not trial-defined
↗
WHAT ABOUT TITRATION?TB-500 does not have a trial-defined step-up titration schedule.
Community protocols more often describe a change of phase — a higher-frequency loading period followed by a lower-frequency maintenance period. Other protocol sites publish daily staged examples. This variation reflects a lack of established human dosing evidence; it does not show that one approach is better.
COMMUNITY / EDITORIAL EXAMPLE
NOT CLINICAL GUIDANCEDaily editorial example
This daily pattern is a separate community description from the weekly patterns shown on this page. Neither is an established human TB-500 regimen, and full-length thymosin beta-4 studies do not validate it.
1Weeks 1–2
500 mcg (0.5 mg)Every day · amount each time
2Weeks 3–4
600 mcg (0.6 mg)Every day · amount each time
3Weeks 5–8
750 mcg (0.75 mg)Every day · amount each time
4Weeks 9–12
1 mgEvery day · amount each time
What the figures showInjection under the skin, as described in the example. This copy stops after twelve weeks. The example does not establish a safe course length, a break or a repeat cycle.
Use an editable calendar copyReview the amounts, days and stages in the planner before saving. These figures do not establish how long a prepared vial remains usable.Open the calendar planner
VIAL MATHSSee a worked TB-500 example
Calculation example only. The amount below demonstrates the maths; it does not choose a dose or a preparation method.
- Amount in the vial
- 10 mg
- Final liquid volume
- 3 mL
- Example amount
- 2 mg
- Find the concentration10 mg ÷ 3 mL = 3.333 mg/mL
- Convert the amount to liquid volume2 mg ÷ concentration = 0.6 mL
- Read the U-100 volume marking0.6 mL × 100 = 60 U-100 units
The calculation uses the full concentration before rounding the display. U-100 markings measure volume; they are different from a medicine’s international units (IU). Different vial contents or liquid volumes require a new calculation.
Arithmetic vial yield5 amounts of 2 mg, before handling losses or discard limits. This is a quantity estimate, not a shelf-life estimate.
WORK WITH THE NUMBERS
Calculator tools
Translate a figure you are reviewing into vial, liquid-volume and syringe calculations without treating the example as a recommendation.
Important context: the figures above summarise commonly repeated public/community protocols. They are not established human dosing instructions and have not been validated in a controlled TB-500 trial.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with TB-500
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDTB-500
→
COMMUNITY STACKWolverine Stack
BPC-157 + TB-500
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
Safety & status context
SAFETY & STATUS
What should be kept in view?
TB-500 has a plausible biological rationale, but the direct human safety database is much thinner than the related thymosin-β4 literature.
CURRENT EVIDENCE POSITIONDirect human TB-500 data remain sparse
INVESTIGATIONALHuman exposure data
Very limitedFDA's current review says it has not identified human exposure data for drug products containing the thymosin β4 fragment known as TB-500.
Product quality matters
ImportantPeptide aggregation, impurities, formulation and manufacturing quality can influence the behaviour and immunogenicity of an injectable peptide product.
Fragment vs parent peptide
Keep separateSafety or efficacy findings for full-length thymosin β4 should not automatically be assigned to the shorter acetylated TB-500 fragment.
Competitive sport
ProhibitedThymosin β4 and TB-500 are prohibited in sport under the World Anti-Doping Code growth-factor category.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
6 sourcesSources used on this profile
Direct TB-500 researchTB-500 metabolism and wound-healing activity in vitroPubMed · PMID 38382158 ↗Motif-level preclinical researchThe actin-binding site on thymosin beta4 promotes angiogenesisPubMed · PMID 14500546 ↗Related mechanistic researchBiological activities of thymosin beta4 defined by active sites in short peptide sequencesPubMed · PMID 20179146 ↗Parent-peptide human researchFull-length thymosin β4 in dermal healingPubMed · PMID 23050815 ↗Professional sourceUSFDA safety review ↗Professional sourceCompetitive sportSport Integrity / WADA context ↗
CURRENT STATUS
How to interpret its position today
Unapproved / insufficient human safety data
FDA says it has not identified human exposure data for drug products containing the thymosin beta-4 fragment known as TB-500 and has highlighted potential immunogenicity, aggregation and peptide-impurity concerns.
FDA safety review ↗Prohibited
Thymosin beta-4 / TB-500 is prohibited in sport under the World Anti-Doping Code growth-factor category.
Sport Integrity / WADA context ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.